Results 91 to 100 of about 12,380 (194)
Acta Scientiarum. Health Sciences, 2014 Current study develops and validates a dissolution test for Prasugrel hydrochloride 10 mg in coated tablets. After sink condition, filters and drug stability were evaluated, the discriminatory dissolution conditions were achieved with a USP apparatus 1 ...
Camila Rigobello +2 more
doaj +1 more source
, 2015 Insgesamt 355 Patienten wurden unter antithrombozytärer Therapie mittels Impedanzaggregometrie auf das Vorliegen von Low-Response untersucht. Als Agonist dienten hierbei Arachidonsäure und ADP.
Franken, Cora Christina
core
, 2015 Ensayo clínico unicéntrico abierto y cruzado donde se evaluó el efecto en voluntarios sanos sobre la función plaquetaria en función de la administración intravenosa de acetilsalicilato de lisina o aspirina oral.
Macaya Miguel, Carlos +9 more
core +1 more source
Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes
, 2019 Background The relative merits of ticagrelor as compared with prasugrel in patients with acute coronary syndromes for whom invasive evaluation is planned are uncertain.
Schüpke, Stefanie +41 more
core +1 more source
Pharmacokinetics and pharmacodynamics of prasugrel in healthy Japanese subjects
, 2016 This randomized double-blind and placebo-controlled study assessed the pharmacodynamics and pharmacokinetics of prasugrel in healthy adult Japanese male subjects after single (n = 50) and multiple (n = 40) oral administration.
Ikeda, Yasuhiko +5 more
core +1 more source
, 2019 The value of platelet function testing (PFT) in predicting clinical outcomes and guiding P2Y12-inhibitor treatment is uncertain. In a pre-specified sub-study of the TROPICAL-ACS trial, we assessed ischaemic and bleeding risks according to high platelet ...
Ruzsa Zoltán +14 more
core +1 more source
Frontiers in Cardiovascular MedicineBackgroundData are lacking on the effects of the alternation of P2Y12 receptor antagonists (P2Y12) on bleeding and outcome in patients with myocardial infarction (MI) with cardiogenic shock (CS). We compared the effects of different P2Y12 and alternation
Vojko Kanic, Gregor Kompara
doaj +1 more source
, 2018 BACKGROUND: Prasugrel is a thienopyridine that inhibits platelet aggregation more rapidly and effectively than clopidogrel, with an increased bleeding risk.
Fanny Bonhomme +9 more
core +1 more source
MCBS (Molecular and Cellular Biomedical Sciences)Background: In acute coronary syndrome (ACS), antiplatelet therapy is crucial for inhibiting platelet aggregation. Dual antiplatelet therapy (DAPT) commonly employs aspirin along with clopidogrel, prasugrel, or ticagrelor. This is well known that aspirin
Muhammad Naufal Hibatullah +2 more
doaj +1 more source